Hoermann Rudolf, Midgley John E M, Giacobino Adrienne, Eckl Walter A, Wahl Hans Günther, Dietrich Johannes W, Larisch Rolf
Department of Nuclear Medicine, Klinikum Luedenscheid, Luedenscheid, Germany.
Clin Endocrinol (Oxf). 2014 Dec;81(6):907-15. doi: 10.1111/cen.12527. Epub 2014 Jul 7.
We examined the interrelationships of pituitary thyrotropin (TSH) with circulating thyroid hormones to determine whether they were expressed either invariably or conditionally and distinctively related to influences such as levothyroxine (L-T4) treatment.
This prospective study employing 1912 consecutive patients analyses the interacting equilibria of TSH and free triiodothyronine (FT3) and free thyroxine (FT4) in the circulation.
The complex interrelations between FT3, FT4 and TSH were modulated by age, body mass, thyroid volume, antibody status and L-T4 treatment. By group comparison and confirmation by more individual TSH-related regression, FT3 levels were significantly lower in L-T4-treated vs untreated nonhypothyroid autoimmune thyroiditis (median 4·6 vs 4·9 pm, P < 0·001), despite lower TSH (1·49 vs 2·93 mU/l, P < 0·001) and higher FT4 levels (16·8 vs 13·8 pm, P < 0·001) in the treated group. Compared with disease-free controls, the FT3-TSH relationship was significantly displaced in treated patients with carcinoma, with median TSH of 0·21 vs 1·63 (P < 0·001) at a comparable FT3 of 5·0 pm in the groups. Disparities were reflected by calculated deiodinase activity and remained significant even after accounting for confounding influences in a multivariable model.
TSH, FT4 and FT3 each have their individual, but also interlocking roles to play in defining the overall patterns of thyroidal expression, regulation and metabolic activity. Equilibria typical of the healthy state are not invariant, but profoundly altered, for example, by L-T4 treatment. Consequently, this suggests the revisitation of strategies for treatment optimization.
我们研究了垂体促甲状腺激素(TSH)与循环甲状腺激素之间的相互关系,以确定它们是始终表达还是有条件地表达,以及它们与左甲状腺素(L-T4)治疗等影响因素是否存在独特关联。
这项前瞻性研究连续纳入1912例患者,分析了循环中TSH与游离三碘甲状腺原氨酸(FT3)和游离甲状腺素(FT4)的相互作用平衡。
FT3、FT4与TSH之间的复杂相互关系受到年龄、体重、甲状腺体积、抗体状态和L-T4治疗的调节。通过组间比较以及更多与TSH相关的个体回归分析证实,在接受L-T4治疗的非甲状腺功能减退自身免疫性甲状腺炎患者中,FT3水平显著低于未治疗患者(中位数分别为4.6与4.9 pm,P < 0.001),尽管治疗组的TSH较低(1.49与2.93 mU/l,P < 0.001)且FT4水平较高(16.8与13.8 pm,P < 0.001)。与无病对照组相比,接受治疗的癌症患者中FT3-TSH关系明显不同,在两组FT3均为5.0 pm时,治疗组的TSH中位数为0.21,而对照组为1.63(P < 0.001)。计算得到的脱碘酶活性反映了这种差异,即使在多变量模型中考虑了混杂影响后,差异仍然显著。
TSH、FT4和FT3在定义甲状腺表达、调节和代谢活动的总体模式中各自发挥着独特但又相互关联的作用。健康状态下典型的平衡并非一成不变,而是会因L-T4治疗等因素而发生深刻改变。因此,这表明需要重新审视优化治疗策略。